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Multidrug-resistant tuberculosis (MDR TB) in Africa 
may be more prevalent than previously appreciated. Fac-
tors leading to development of drug resistance need to be 
understood to develop appropriate control strategies for na-
tional programs. We gathered estimates of MDR TB rates 
for 39 of 46 countries in Africa. The relationship between 
MDR TB rates and independent factors was analyzed by 
using correlation and linear regression models. Our ﬁ  ndings 
indicate that drug resistance surveys in Africa are critically 
needed. MDR TB rates must be assessed in countries with-
out these surveys. In countries that have conducted a drug 
resistance survey, a new survey will determine evolution of 
drug resistance rates. We found no correlation between high 
MDR rates and TB incidence, HIV/TB co-infection rates, or 
year of introduction of rifampin. Results show that the re-
treatment failure rate was the most predictive indicator for 
MDR TB. Current category II drug regimens may increase 
MDR TB.
G
lobal control of tuberculosis (TB) has been jeopardized 
by 2 major threats: HIV/AIDS and multidrug-resistant 
TB (MDR TB). MDR TB is deﬁ  ned as strains of Mycobac-
terium tuberculosis that are resistant to at least isoniazid 
and rifampin (1). Drug resistance has reached alarming 
levels with the emergence of strains that are virtually un-
treatable with existing drugs. The recent report of an out-
break of extensively drug-resistant TB (XDR TB) in South 
Africa (2), with its extremely high case-fatality rate, has 
drawn wide attention. However, the more general problem 
of MDR TB, with an estimated 450,000 cases worldwide 
annually, has been recognized since the ﬁ  rst World Health 
Organization (WHO) global survey on drug resistance in 
the late 1990s (3).
According to the WHO Global Report on Anti-tuber-
culosis Drug Resistance in the World (1), MDR TB strains 
have emerged in all regions of the world. However, despite 
the dramatic increase in TB rates in Africa, MDR TB ap-
pears nearly absent from this continent, which, until recent-
ly, reported the lowest median levels of drug resistance.
Two explanations have been most commonly put for-
ward to explain these reported low levels of MDR TB in Af-
rica. The ﬁ  rst explanation is the presence of well-function-
ing control programs in Africa. Eighty-nine percent of the 
population in the WHO-deﬁ  ned region of Africa is covered 
by directly observed therapy, short course (DOTS), which is 
similar to the global average (4). However, there is discor-
dance between purported DOTS coverage and national TB 
program (NTP) efﬁ  cacy. Each year, countries with the low-
est case detection and cure rates are clustered in the WHO-
deﬁ   ned Regional Ofﬁ   ce for Africa (AFRO) region (4). 
This suggests that NTPs in Africa are not performing better 
than their Eastern European or South American counter-
parts, where MDR TB rates have already reached alarming 
levels. The functional status of many programs in Africa 
is difﬁ  cult to assess with certainty, and the high incidence 
rates on that continent indicate that programs may not be 
functioning well. Low case-detection rates alone may not 
lead to development of MDR TB. Other factors that might 
favor development of MDR TB include the availability of 
drugs on the open market and a private sector that delivers 
drugs to the population in an unregulated fashion. 
The second explanation is the recent introduction of 
rifampin in Africa. It is often stated that because rifampin 
was only recently introduced in Africa on a large scale, 
there has been relatively little time for resistance to devel-
op. However, development of rifampin resistance may be 
spurred by HIV infection, and such resistance appears to 
develop rapidly (5–10).
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Our research described in this report indicates the 
possibility of a third and straightforward explanation: 
ﬁ  eld results for Africa are still incomplete, despite the re-
cent publication of the WHO Fourth Global Report (1). 
This report is the result of independent drug resistance 
surveys (DRSs) conducted throughout the world follow-
ing strict guidelines. The number of countries participat-
ing in the overall survey was low, especially in the Africa 
region. Furthermore, one might speculate that those coun-
tries capable of providing DRS data may have been the 
ones most likely to have a well-functioning NTP, labora-
tory structures, and transport networks, which would bias 
overall reporting. However, even if this is not the case, 
overall low levels of reporting make ﬁ  ndings of the report 
questionable.
Consequently, the low level of reported drug resistance 
in Africa may not be an accurate reﬂ  ection of reality, and 
the limited evaluation may be responsible for this skewed 
portrayal. Lack of comprehensive national DRS data from 
all countries in Africa is a barrier to understanding the 
magnitude of prevalence and incidence of MDR. In light 
of the added threat of XDR TB within the African context 
of high HIV prevalence, a thorough assessment of TB drug 
resistance and evaluation of data-speciﬁ  c deﬁ  ciencies is ur-
gently needed.
Our report aims to provide a more accurate assessment 
of MDR TB in Africa by incorporating all the latest avail-
able data and published estimates. In addition to suggesting 
that the effect of MDR TB in Africa is higher than previ-
ously thought, our report explores trends and relationships 
among case detection, treatment success, retreatment fail-
ure, and HIV rates relative to MDR TB. We attempted to 
identify population-based factors associated with MDR TB. 
Given the limited healthcare funding and substantial inci-
dence of HIV in Africa, even a relatively low but increasing 
tide of MDR TB can lead to disastrous consequences for 
this continent.
Methods
Search Strategy
PubMed and Medline databases were searched for 
reviews and original reports based on primary studies by 
using the keywords tuberculosis, Mycobacterium tubercu-
losis, multidrug-resistant, and Africa. English and French 
language articles were reviewed.
Study Selection
Data were assembled into a comprehensive composite 
on the basis of several criteria. Published MDR TB rates 
from WHO were prioritized because of their reliability and 
because they are the result of DRSs conducted throughout 
the world following strict guidelines: new patients were 
clearly distinguished from those with previous TB treat-
ment, and optimal laboratory performance was ensured 
and maintained through links with supranational reference 
laboratories.
Second, data on MDR TB were collected from peer-
reviewed journals. Articles were considered only if spe-
ciﬁ  c criteria were met: 1) new patients needed to be dis-
tinguished from patients with prior TB treatment; 2) the 
number of conﬁ  rmed TB cases needed to be statistically 
signiﬁ  cant; and 3) the study needed to be nationwide or the 
population covered needed to be greater than one fourth of 
the total population.
For countries where data were unavailable through 
WHO reports or recent peer-reviewed journals, published 
formulaic estimates by Zignol et al. were used (11). The 
formula considers 9 independent variables considered like-
ly to be associated with drug resistance and used in regres-
sion analyses. Resulting estimates compare favorably with 
known MDR TB values.
Data Extraction
The following data were tabulated for all forms of TB 
for all countries under scrutiny. Presurvey and postsurvey 
variables were annual country-speciﬁ  c indicators averaged 
from 1995 to the year of the drug resistance survey (pre-
survey) and from year after drug resistance survey to 2005 
(postsurvey). These variables included TB incidence rate, 
case detection rate, treatment rates (category I: cured, com-
pleted, failure, default and success), and retreatment rates 
(category II: cured, completed, failure, default, and success). 
Year 2005 variables were published MDR TB estimates for 
new cases of pulmonary TB, HIV prevalence among adults 
15–49 years of age, TB-related death rate, HIV/TB co-in-
fection rate, male-to-female ratio of case notiﬁ  cation rate, 
and health funding per capita (US dollars) in 2002 obtained 
from the United Nations Development Program (http://hdr.
undp.org/statistics/data/indic/indic_52_1_1.html).
Combined MDR TB rates were compiled for 39 of 
the 46 countries in the AFRO region. For 21 of those 39 
countries, MDR TB rates were gathered from either WHO 
reports or peer-reviewed articles. For the remaining 18 
countries, MDR TB rates were reported by using a formula 
described by Zignol et al. (11). No DRS data or formu-
las were available for 6 countries, Cape Verde, Comoros, 
Liberia, Mauritania, Sao Tome and Principe, and the Sey-
chelles, which account for only 20,475 of the 2,528,915 TB 
cases in Africa (4). Additionally, the accuracy of annual 
data from Mauritius was deemed questionable and thus ex-
cluded from further analysis.
Regression Analysis of Continuous Variables
The unadjusted associations between continuous inde-
pendent variables and MDR TB rates were evaluated by us-
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ing a linear correlation matrix. Independent variables highly 
(p<0.05) or marginally (p<0.10) predictive of the outcome 
in unadjusted models were included in further linear mul-
tivariable modeling. In addition, interactions between case 
detection, treatment failure, and retreatment failure rates 
were tested by using univariate linear regression analyses. 
All analyses were conducted in Stata Statistics version 9.2 
(StataCorp, College Station, TX, USA).
Analysis of Presurvey and Postsurvey 
Continuous Variables
The change between presurvey and postsurvey aver-
ages (average value from 1995 to year of drug resistance 
survey, and year of drug resistance survey to 2005, re-
spectively) for each continuous independent variable was 
evaluated by using the nonparametric Wilcoxon signed 
rank test. Given the small sample size, these variables were 
not assumed to be normal. A change between presurvey 
and postsurvey was deemed statistically signiﬁ  cant if the p 
value was <0.05 and marginally signiﬁ  cant if <0.10.
Categorical Trend Analysis
In addition to relationships between continuous MDR 
TB rates and independent factors, a categorical analysis of 
MDR TB was conducted. Countries were divided into 3 
categories (tertiles) on the basis of MDR TB rates: (0.0–1.7, 
1.8–2.1, and >2.2 deﬁ  ned as low, middle, and high MDR 
rates categories, respectively). For each TB-related indi-
cator, a univariate trend across the 3 MDR TB categories 
(low, middle, and high) was assessed. Trend analysis was 
conducted by using the nptrend function in Stata Statistics 
version 9.2 (StataCorp), which performs a nonparametric 
trend test of rank sums across ordered groups. A trend was 
deemed statistically signiﬁ  cant if the p value was <0.05 and 
marginally signiﬁ  cant if <0.10.
Results
MDR TB Rates in Africa
Data on prevalence of MDR TB among all TB cases 
collected from various WHO publications and published 
peer-reviewed articles are shown in Table 1. The 39 coun-
tries considered in this study encompass ≈99% of total es-
timated incident or prevalent TB cases (all forms) in the 
AFRO region. The proportion of MDR TB among all TB 
cases varies from 5.8% in the Democratic Republic of Con-
go to virtually 0% in Kenya. The median MDR TB rate was 
≈1.9% (Table 2).
The situation in Africa for MDR TB among all com-
bined TB cases is depicted in a series of related maps (Fig-
ure). The ﬁ  rst map is reproduced and translated from the 
WHO Third Global Report published in 2004 (40) (Figure, 
panel A). The coloring scheme was translated into the 3 
categories used in this report, and the continent appears 
particularly devoid of MDR TB.
Panel B of the Figure includes data from various recent 
WHO publications, peer-reviewed journal articles, and the 
Fourth Global Report published in 2008 (1). Indications of 
geographic clustering are apparent; countries with a high 
prevalence of MDR TB are clustered in the southeastern 
and central regions of Africa. Panel B of the Figure also 
shows the 11 countries that have MDR TB rates >2.0 of 
all combined TB cases, including Democratic Republic of 
Congo, Rwanda, Equatorial Guinea, and Senegal, which 
were not included the WHO Third Global Report.
Panel C of the Figure includes formulaic estimates. On 
the basis of these estimates, high levels of MDR TB are 
not only located in the southeastern and central regions, but 
also in West Africa, which differs from results of the WHO 
Third Global Report.
Effect of Year of Introduction of Rifampin
Dates of rifampin introduction were available for 11 
countries (Table 3). Dates of introduction are clustered 
around the mid-1980s. The earliest and latest known intro-
ductions of rifampin were 1979 in South Africa and 1989 in 
Zambia. Zambia has a middle-level rate of MDR TB, South 
Africa has a high rate, and other countries have low rates. 
No clear association between date of rifampin introduction 
and MDR rates could be discerned.
Indicators for Continuous MDR Rates
Presurvey independent variables were evaluated 
through 3 types of linear regression analysis: correlation 
(Table 4), univariate, and multivariate regression (data not 
shown). Regarding associations with MDR rates, correla-
tion analysis showed a signiﬁ  cant association with retreat-
ment failure rate (p = 0.043, r2 = 0.119). Several other uni-
variate and multivariate linear models, such as treatment 
failure × retreatment failure and case detection × treatment 
failure × retreatment failure, were marginally signiﬁ  cant. 
However, no other models that used presurvey data were 
more predictive than retreatment failure rate alone. For 
postsurvey variables, univariate analysis (Table 4) also 
showed a statistically signiﬁ  cant association between MDR 
rates and retreatment failure rates.
Comparison of Presurvey and Postsurvey 
Indicator Averages
Using the Wilcoxon signed rank test, we determined 
that 5 of 14 indicators showed a signiﬁ  cant (p<0.05) change 
between presurvey and postsurvey years. Treatment default 
showed a decrease; incidence rate, treatment cured, treat-
ment success, and retreatment death rate increased between 
time intervals.
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 9, September 2008  1347 PERSPECTIVE
Indicators for MDR TB Categories
When considered through nonparametric trend analysis, 
there was a marginally signiﬁ  cant positive association be-
tween MDR TB categories and retreatment failure rates (data 
not shown). Median retreatment failure rates were higher 
within relatively higher categorized MDR TB countries.
Discussion
Our visual mapping indicates that MDR TB is likely 
to be more prevalent in Africa than previous reports indi-
cated. The latest WHO Global Report on Anti-tuberculosis 
Drug Resistance in the World published in March 2008 (1) 
indicated rates of drug-resistant TB in Africa to be among 
the lowest worldwide. However, as of April 2008, 25 of the 
46 countries in the AFRO region still had not completed a 
national study to investigate levels of MDR TB. By incor-
porating the latest national studies on MDR TB in Africa, 
and classifying countries on the basis of MDR TB rates 
in combined cases of TB, we found worrisome trends: 6 
countries that were not included in the WHO Third Global 
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Table 1. Prevalence of MDR TB among combined TB cases by country, Africa* 
Country 
MDR resistance 
value, % (95% CI)  Nationwide study  Year  Reference
References for 
other convenience 
sample surveys 
Algeria 1.4†(0.5–2.7) NA NA (11)
Angola 2.1† (0.6–8.9) NA NA (11)
Benin 1.0† (0.2–3.9) NA NA (11)
Botswana  1.6‡ (0.8–1.9)  Countrywide survey  2002 (1)( 17,18)
Burkina Faso  2.6† (8.8–11.0)  NA NA (11)( 19)
Burundi 1.4§ Bujumbura survey 2006 (20)
Cameroon 2.0† (0.6–8.9)  NA NA (11)( 12,13)
Central African Republic  2.2¶ (1.0–3.4)  Countryside survey  1998 (1)( 21)
Chad 1.9† (0.5–9.0) NA (11)( 22)
Congo, Brazzaville  1.8† (0.5–8.2)  NA NA (11)
Côte d’Ivoire  5.4† (3.2–8.4) NA NA (11)( 23)
Democratic Republic of Congo  5.8¶ (0.6–10.3) Kinshasa survey  1999 (1)
Equatorial Guinea  3.4§ 5 of 18 survey districts  2004 (24)
Eritrea 1.9† (0.5–9.0) NA NA (11)
Ethiopia 2.5¶ Countrywide survey  2005 (1)( 25–27)
Gabon 1.8† (0.6–8.1) NA NA (11)
Gambia 0.4¶ (0.0–1.4)  Countrywide survey  2000 (28)
Ghana 1.9† (0.5–8.7) NA NA (11)
Guinea 2.1¶ (1.0–3.0)  Sentinel sites survey  1998 (1)
Guinea-Bissau 2.6† (0.8–1.4) NA NA (11)
Kenya  0¶ (0.0–1.1)  Nearly countrywide survey 1995 (1)( 29–31)
Lesotho 1.6¶ (0.4–2.6)  Countrywide survey  1995 (1)
Madagascar 0.7¶ (0.7–10.3)  Countrywide survey  2007 (1)( 14)
Malawi 1.9† (0.5–9.3)  NA NA (11)( 15,16)
Mali 1.5† (0.3–7.9) NA NA (11)
Mauritius 1.4† (0.4–6.4) NA NA (11)
Mozambique 3.5¶ (2.5–4.6)  Countrywide survey  1999 (1)( 32,33)
Namibia 1.5† (0.4–7.1) NA NA (11)
Niger 2.7† (0.8–11.5) NA NA (11)
Nigeria 2.0† (0.6–9.3) NA NA (11)
Rwanda 4.6 Countrywide  survey  2005 (34)
Senegal 4.3¶ (0.8–10.6)  Countrywide survey  2006 (1)
Sierra Leone  3.1¶ (0.3–4.0)  Nearly countrywide survey 1997 (1)
South Africa  3.1¶ (2.2–3.0)  Countrywide survey  2002 (1)( 2,35–39)
Swaziland  1.9¶ (0.5–3.1)  Countrywide survey  1995 (1)
Togo 2.1† (0.6–9.5) NA NA (11)
Uganda 1¶ (0.1–1.6)  3 district surveys  1997 (1)
Tanzania 1¶ (0.6–9.8)  Countrywide survey  2007 (1)
Zambia 1.8¶ (0.8–3.1)  Countrywide survey  2000 (1)
Zimbabwe  2.2¶ (1.3–4.0)  Nearly countrywide survey 1995 (1)
*TB, tuberculosis; MDR TB, multidrug-resistant TB; CI, confidence interval; NA, not available. 
†Formulaic.
‡National Drug Resistance survey. 
§Convenience sample survey. 
¶World Health Organization. Underreported Threat of MDR TB in Africa
Report published in 2004 have MDR TB rates >2.0% of all 
combined TB cases. This ﬁ  nding suggests that completing 
DRSs for all or most countries in the AFRO region is ur-
gently needed and that the MDR TB threat in Africa could 
be much higher than originally assessed by WHO in its 
previous report in 2004. Drug-resistant strains, along with 
HIV/AIDS, are causing the biggest challenge to efﬁ  cient 
management and control of TB.
The lower rates of MDR TB in Africa, when compared 
with rates in Eastern Europe or South America, could be 
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Table 2. Descriptive statistics for country-specific MDR rates and other TB-related factors, Africa* 
Average, presurvey years  
(1995 to survey year)
Average, postsurvey years  
(year after survey to 2005)
Wilcoxon signed 
rank test†
Factor 
No., mean, 
median Range SD
No., mean, 
median Range SD
Z-score, p 
value‡
MDR rates 39, 2.21, 1.9 0.0–5.8 1.2
Incidence rate/100,000/ y 39, 116, 109 22–228 40.6 33, 152, 150 25–308 70.2 –3.92, 0.0001§
Case detection rate (new ss+) 39, 47.2, 49.8 8.2–86.0 22.4 32, 55.5, 56.2 13.6–112.2 27.5 –1.52, 0.130
Treatment indicators 
  Cured 36, 50.9, 52.3 17.1–74.6 14.2 32, 56.2, 59.0 16.6–78.4 14.5 –3.58, 0.0001§
  Completed 39, 14.3, 12.4 3.1–47.4 9.8 32, 13.9, 11.1 1.3–38.5 8.9 1.27, 0.206
  Died 36, 6.7, 6.1 2.6–19.5 3.3 32, 7.4, 7.2 0.7–17.1 3.5 –0.36, 0.721
  Failed 36, 1.8, 1.6 0.0–7.8 1.5 32, 1.7, 1.3 0.2–5.3 1.2 –0.34, 0.738
  Defaulted 36, 14.1, 13.2 4.4–41.4 6.8 32, 11.9, 10.9 2.6–39.7 7.4 2.48, 0.013§
  Succeeded 36, 65.2, 67.0 33.0–83.5 10.3 32, 70.0, 70.5 37.1–90.3 10.3 –3.56, 0.0001§
Retreatment indicators 
  Cured 35, 47.1, 48.0 11.1–71.3 16.2 29, 48.5, 52.0 2.9–72.4 17.3 –1.22, 0.221
  Completed 35, 14.1, 12.7 0.0–46.6 8.7 29, 13.4, 9.8 0.5–40.8 10.0 1.49, 0.135
  Died 35, 7.9, 7.7 0.0–22.7 4.1 29, 10.4, 10.1 1.6–21.4 4.5 –2.27, 0.023§
  Failed 35, 3.6, 2.8 0.2–14.6 2.8 29, 3.2, 3.0 –8.9 2.2 0.18, 0.861
  Defaulted 35, 14.6, 12.8 4.6–29.3 6.9 29, 11.9, 10.9 2.7–26.7 6.2 1.49, 0.135
  Succeeded 35, 61.1, 62.6 30.3–81.3 13.1 29, 61.9, 64.6 23.1–81.8 14.2 0.18, 0.861
Year 2005 only variables 
  Prevalence/100,000 38, 497, 513 55–936 178
  TB mortality rate/100,000/ y 39, 79, 73 2–304 48
  HIV/TB co-infection, % 39, 26.8, 19.0 0.5–75.0 20.5
  Male/female ratio: case  
 notifications
36, 1.5, 1.5 0.7–2.6 0.4
  Health expenditures (US $ per 
 capita) 
39, 107, 51 15–689 131
*MDR, multidrug resistance; TB, tuberculosis; ss+, sputum sample positive.  
†Based on presurvey minus postsurvey values. A negative Z-score is indicative of an increase over time. 
‡Marginally statistically significant trend (p<0.10). 
§Statistically significant trend (p<0.05). 
Figure. Prevalence of multidrug resistance (MDR) in Africa among combined tuberculosis cases. A) Data collected from the Third Global 
Report on Anti-tuberculosis Drug Resistance in the World of the World Health Organization (WHO) published in 2004 (40). B) Data from 
various recent WHO publications, peer-reviewed journal articles, and WHO’s Fourth Global Report (1). C) Formulaic estimates of Zignol 
et al. (11). AFRO, WHO Regional Ofﬁ  ce for Africa.PERSPECTIVE
related to the fact that for many years Africa was neglected 
and TB was not treated. Alternatively, later introduction 
of rifampin in drug regimens is often cited as an explana-
tion for these low rates. However, for the few countries for 
which data were available, we did not ﬁ  nd a statistically 
signiﬁ  cant relationship between year of rifampin introduc-
tion and level of MDR TB.
We subsequently set out to investigate linear associa-
tions between country-speciﬁ  c factors as well as categori-
cal trends in TB management to discriminate levels of 
MDR TB in Africa. Retreatment failure rate was the most 
predictive indicator of MDR TB rates; other variables such 
as average case detection rate (1995–2005), average TB in-
cidence rate (1995–2005), TB prevalence (2005), and HIV/
TB co-infection (2005) did not show a linear relationship. 
Categorical analysis showed similar results.
One can speculate about the reasons that retreatment 
failure rates may be associated with higher rates of MDR 
TB. The relationship may simply be an association without 
causation, i.e., that retreatment fails because a given patient 
may already have MDR TB. In that sense, retreatment fail-
ure is simply a marker for preexisting MDR TB. However, 
it is also possible that retreatment may be a cause of MDR 
TB. Current WHO recommendations for retreatment regi-
mens could lead to development of MDR TB or XDR TB 
in many instances because suggested retreatment regimens 
potentially amount to addition of 1 drug to a failing regi-
men, thereby intensifying the level of drug resistance.
We subsequently investigated whether combining the 
retreatment failure rate with other indicators in our model 
could generate a predictive combination for MDR TB 
rates. Whereas the univariate linear and the multivariate 
regression model showed a marginally signiﬁ  cant associ-
ation with either treatment failure, case detection rate, or 
both, retreatment failure as a sole indicator remained the 
most signiﬁ  cant. This ﬁ  nding may indicate that, regard-
less of the successful record of a given NTP in detecting 
cases and subsequently successfully treating them with a 
category I regimen, the highest MDR TB rates were found 
in the countries with the highest retreatment failure rates 
(category II).
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Table 3. Years of introduction of rifampin in 11 African countries 
Country Date
Algeria 1980
Benin 1986
Botswana 1986
Côte d’Ivoire  1985
Gambia 1986
Malawi 1986
Mozambique 1986
Senegal 1986
South Africa  1979
Tanzania 1982
Zambia 1989
Table 4. Correlation analysis between country-level TB-related indicators and rates of MDR TB in African countries* 
Average, presurvey years  Average, postsurvey years 
Factor  Coefficient p value†  Coefficient p value† 
Incidence rate/100,000/y  0.09 0.592 0.03 0.865
Case detection rate (new ss+)  –0.14 0.380 –0.10 0.585
Treatment indicators 
 Cured  0.03 0.842 0.18 0.330
 Completed  –0.13 0.446 –0.21 0.256
 Died  –0.10 0.542 0.04 0.840
 Failed  0.12 0.498 0.17 0.341
 Defaulted  –0.07 0.664 –0.05 0.781
 Succeeded  –0.08 0.653 0.08 0.676
Retreatment indicators 
 Cured  –0.03 0.881 0.08 0.674
 Completed  –0.20 0.258 –0.24 0.217
 Died  –0.06 0.728 –0.11 0.588
 Failed  0.34 0.043‡ 0.41 0.029‡
 Defaulted  0.04 0.798 0.12 0.540
 Succeeded  –0.16 0.351 –0.07 0.728
Year 2005 only variables 
 Prevalence/100,000  0.14 0.404
 Mortality  rate/100,000/y  0.02 0.894
  HIV/TB co-infection (%)  –0.09 0.593
  Male/female ratio: case notifications  –0.05 0.787
  Health expenditures (US $ per capita)  –0.01 0.956
*TB, tuberculosis; MDR TB, multidrug-resistant TB; ss+, sputum sample positive. 
†Marginally statistically significant trend (p<0.10). 
‡Statistically significant trend (p<0.05). Underreported Threat of MDR TB in Africa
We also investigated levels of variables reported in 
years after a DRS to determine whether the result of the sur-
vey affected these variables. Five of the 14 variables mea-
sured showed a statistically signiﬁ  cant change over time: 4 
variables (case detection rates, treatment cure rates, treat-
ment success rates, and retreatment death rates) increased 
after the survey, and treatment defaulters decreased. Unfor-
tunately, we cannot determine the effect of those 5 indica-
tors on MDR TB rates because most countries surveyed re-
ported only 1 DRS. Retreatment failure, which was shown 
to be the most predictive indicator of MDR TB rates, did 
not change over time. This ﬁ  nding suggests that MDR TB 
rates have increased in the years after the survey. To draw 
a parallel with physics, if the acceleration of an object re-
mains constant over time, its speed increases. Therefore, it 
seems critical for countries who have already reported DRS 
results to undergo a second DRS to monitor the evolution 
of the MDR TB rate originally reported and help determine 
the effect of newly installed healthcare and TB treatment 
systems on drug resistance. For example, the only DRS re-
ported from Kenya (conducted in 1995) reported an MDR 
TB rate of 0.0%. In 2008, the validity of this result is highly 
questionable given the recently published high MDR TB 
rates of neighboring countries (Figure).
This research was limited by the differing country-lev-
el data estimates and the ecologic study design. Twenty one 
of the 39 countries analyzed have TB estimates from WHO 
or peer-reviewed journals. However, the other 19 countries 
required formulaic estimates of MDR TB rates. The ef-
fect of these differing estimation methods depends on the 
congruity of future country-level estimates relative to the 
ﬁ  gures accepted in this study. Therefore, analyses should 
be repeated as more deﬁ  nitive estimates become available. 
Second, the ecologic study design, which analyzes these 
TB-related factors on a population level, limits the transfer-
ence of any apparent relationships to the individual level. 
However, evidence shows that an effective DOTS program 
can limit the development of drug resistance on the indi-
vidual TB patient level (41). Lastly, the small sample size 
of 39 countries limits the power to statistically determine 
differences. As a ﬁ  nal note, this report hoped to realize 2 
goals: to provide a composite of MDR TB in Africa and to 
identify relationships and trends.
Trends and relationships aside, MDR TB in Africa is 
a burgeoning obstacle that shows no signs of regression. 
The prevalence of MDR TB remains below the levels seen 
in Central Europe and parts of Latin America. However, 
in Africa, the tragically high HIV prevalence and limited 
funds and infrastructure dedicated to healthcare are serious 
factors. As the outbreak of MDR TB/HIV co-infection in 
New York City in the mid-1990s taught the medical com-
munity, this co-infection is pernicious, difﬁ  cult, and over-
whelmingly expensive to treat. This situation raises the 
question: if the continent is ﬁ  nding difﬁ  culty addressing 
TB, a well-deﬁ  ned disease caused by a well-deﬁ  ned agent, 
which is fully treatable with effective and affordable drugs 
through internationally recommended guidelines, then how 
will the continent fare against MDR TB and XDR TB?
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